Seminars in Pediatric Neurology
Volume 14, Issue 1 , Pages 15-25 , March 2007

Mechanisms of Disease II: Cellular Protein Quality Control

  • Tiago Fleming Outeiro, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Tiago Fleming Outeiro, Alzheimer’s Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129.
    • ,
  • Julie Tetzlaff, PhD

References 

  1. Barral JM, Broadley SA, Schaffar G, et al. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol. 2004;15:17–29
  2. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol. 2004;15:3–16
  3. Anfinsen CB. Principles that govern the folding of protein chains. Science. 1973;181:223–230
  4. Dobson CM. Protein folding and misfolding. Nature. 2003;426:884–890
  5. Daggett V, Fersht A. The present view of the mechanism of protein folding. Nat Rev Mol Cell Biol. 2003;4:497–502
  6. Ellis RJ. Macromolecular crowding: An important but neglected aspect of the intracellular environment. Curr Opin Struct Biol. 2001;11:114–119
  7. Minton AP. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J Biol Chem. 2001;276:10577–10580
  8. Ellis RJ, Pinheiro TJ. Medicine: Danger—Misfolding proteins. Nature. 2002;416:483–484
  9. Kiffin R, Bandyopadhyay U, Cuervo AM. Oxidative stress and autophagy. Antioxid Redox Signal. 2006;8:152–162
  10. Massey AC, Zhang C, Cuervo AM. Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol. 2006;73:205–235
  11. Walter S, Buchner J. Molecular chaperones—Cellular machines for protein folding. Angew Chem Int Ed Engl. 2002;41:1098–1113
  12. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: From nascent chain to folded protein. Science. 2002;295:1852–1858
  13. Ellis J. Proteins as molecular chaperones. Nature. 1987;328:378–379
  14. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet. 1988;22:631–677
  15. Parsell DA, Lindquist S. The function of heat-shock proteins in stress tolerance: Degradation and reactivation of damaged proteins. Annu Rev Genet. 1993;27:437–496
  16. Lindquist S. Heat-shock proteins and stress tolerance in microorganisms. Curr Opin Genet Dev. 1992;2:748–755
  17. Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996;381:571–579
  18. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev. 2002;82:373–428
  19. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 1991;349:132–138
  20. Hershko A, Ganoth D, Pehrson J, et al. Methylated ubiquitin inhibits cyclin degradation in clam embryo extracts. J Biol Chem. 1991;266:16376–16379
  21. Hershko A, Ciechanover A, Heller H, et al. Proposed role of ATP in protein breakdown: Conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A. 1980;77:1783–1786
  22. Ciechanover A, Heller H, Elias S, et al. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci U S A. 1980;77:1365–1368
  23. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001;2:169–178
  24. Braun BC, Glickman M, Kraft R, et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol. 1999;1:221–226
  25. Verma R, Aravind L, Oania R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298:611–615
  26. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature. 2002;419:403–407
  27. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol. 2001;2:195–201
  28. Ballinger CA, Connell P, Wu Y, et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol. 1999;19:4535–4545
  29. Luders J, Demand J, Hohfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem. 2000;275:4613–4617
  30. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395:451–452
  31. Liu Y, Fallon L, Lashuel HA, et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell. 2002;111:209–218
  32. Thomas PJ, Qu BH, Pedersen PL. Defective protein folding as a basis of human disease. Trends Biochem Sci. 1995;20:456–459
  33. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267–298
  34. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(suppl):S10–S17
  35. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840
  36. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998;57:334–337
  37. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  38. Ding TT, Lee SJ, Rochet JC, et al. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 2002;41:10209–10217
  39. Gasser T. Genetics of Parkinson’s disease. J Neurol. 2001;248:833–840
  40. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047
  41. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–608
  42. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256–259
  43. Valenza M, Rigamonti D, Goffredo D, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J Neurosci. 2005;25:9932–9939
  44. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607
  45. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302–305
  46. Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001;105:891–902
  47. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson’s disease. Science. 2001;293:263–269
  48. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat Med. 2001;7:1144–1150
  49. Hyun DH, Lee MH, Halliwell B, et al. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: A mechanism contributing to neurodegeneration?. J Neurochem. 2002;83:360–370
  50. Petrucelli L, O’Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein (Proteasome dysfunction selectively affects catecholaminergic neurons). Neuron. 2002;36(6):1007–1019
  51. McNaught KS, Belizaire R, Jenner P, et al. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett. 2002;326:155–158
  52. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett. 2001;297:191–194
  53. Imai Y, Soda M, Hatakeyama S, et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson’s disease, and enhances its ubiquitin ligase activity. Mol Cell. 2002;10:55–67
  54. Auluck PK, Chan HY, Trojanowski JQ, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science. 2002;295:865–868
  55. Andringa G, Bol JG, Wang X, et al. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain. Neuropathol Appl Neurobiol. 2006;32:157–169
  56. Fan GH, Zhou HY, Yang H, et al. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells. FEBS Lett. 2006;580:3091–3098
  57. Shen HY, He JC, Wang Y, et al. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem. 2005;280:39962–39969
  58. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem. 2005;280:2873–2878
  59. Flower TR, Chesnokova LS, Froelich CA, et al. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson’s disease. J Mol Biol. 2005;351:1081–1100
  60. Gorman AM, Szegezdi E, Quigney DJ, et al. Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. Biochem Biophys Res Commun. 2005;327:801–810
  61. Dong Z, Wolfer DP, Lipp HP, et al. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther. 2005;11:80–88
  62. Klucken J, Shin Y, Masliah E, et al. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem. 2004;25497–25502
  63. McLean PJ, Klucken J, Shin Y, et al. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun. 2004;321:665–669
  64. Flower TR, Chesnokova LS, Froelich CA, et al. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson’s disease. J Mol Biol. 2005;351:1081–1100
  65. Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med. 2002;8:1185–1186
  66. McDonough H, Patterson C. CHIP: A link between the chaperone and proteasome systems. Cell Stress Chaperones. 2003;8:303–308
  67. Shin Y, Klucken J, Patterson C, et al. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem. 2005;280:23727–23734
  68. Miller TW, Messer A. Intrabody applications in neurological disorders: Progress and future prospects. Mol Ther. 2005;12:394–401
  69. Al-Ramahi I, Lam YC, Chen HK, et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem. 2006;281:26714–26724
  70. Hatakeyama S, Matsumoto M, Kamura T, et al. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J Neurochem. 2004;91:299–307
  71. Dickey CA, Yue M, Lin WL, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci. 2006;26:6985–6996
  72. Podlisny MB, Ostaszewski BL, Squazzo SL, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564–9570
  73. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest. 2002;110:1375–1381
  74. Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556–561
  75. Keck S, Nitsch R, Grune T, et al. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem. 2003;85:115–122
  76. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer’s disease. J Neurochem. 2000;75:436–439
  77. Lopez Salon M, Morelli L, Castano EM, et al. Defective ubiquitination of cerebral proteins in Alzheimer’s disease. J Neurosci Res. 2000;62:302–310
  78. Gregori L, Fuchs C, Figueiredo-Pereira ME, et al. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem. 1995;270:19702–19708
  79. Fergusson J, Landon M, Lowe J, et al. Pathological lesions of Alzheimer’s disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci Lett. 1996;219:167–170
  80. Pasinetti GM. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer’s disease dementia. J Neurosci Res. 2001;65:471–476
  81. Gong B, Cao Z, Zheng P, et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006;126:775–788
  82. Loring JF, Wen X, Lee JM, et al. A gene expression profile of Alzheimer’s disease. DNA Cell Biol. 2001;20:683–695
  83. Favit A, Grimaldi M, Alkon DL. Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway. J Neurochem. 2000;75:1258–1263
  84. Schmitt HP. Protein ubiquitination, degradation and the proteasome in neuro-degenerative disorders: No clear evidence for a significant pathogenetic role of proteasome failure in Alzheimer disease and related disorders. Med Hypotheses. 2006;67:311–317
  85. Hamos JE, Oblas B, Pulaski-Salo D, et al. Expression of heat shock proteins in Alzheimer’s disease. Neurology. 1991;41:345–350
  86. Perez N, Sugar J, Charya S, et al. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer’s disease. Brain Res Mol Brain Res. 1991;11:249–254
  87. Renkawek K, Bosman GJ, Gaestel M. Increased expression of heat-shock protein 27 kDa in Alzheimer disease: A preliminary study. Neuroreport. 1993;5:14–16
  88. Shinohara H, Inaguma Y, Goto S, et al. Alpha B crystallin and HSP28 are enhanced in the cerebral cortex of patients with Alzheimer’s disease. J Neurol Sci. 1993;119:203–208
  89. Kakimura J, Kitamura Y, Takata K, et al. Possible involvement of ER chaperone Grp78 on reduced formation of amyloid-beta deposits. Ann N Y Acad Sci. 2002;977:327–332
  90. Dabir DV, Trojanowski JQ, Richter-Landsberg C, et al. Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. Am J Pathol. 2004;164:155–166
  91. Wilhelmus MM, Boelens WC, Otte-Holler I, et al. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res. 2006;1089:67–78
  92. Wilhelmus MM, Otte-Holler I, Wesseling P, et al. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer’s disease brains. Neuropathol Appl Neurobiol. 2006;32:119–130
  93. Yang Y, Turner RS, Gaut JR. The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta40 and Abeta42 secretion. J Biol Chem. 1998;273:25552–25555
  94. Kakimura J, Kitamura Y, Takata K, et al. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 2002;16:601–603
  95. Magrane J, Smith RC, Walsh K, et al. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci. 2004;24:1700–1706
  96. Lee S, Carson K, Rice-Ficht A, et al. Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity. Protein Sci. 2005;14:593–601
  97. Lee S, Carson K, Rice-Ficht A, et al. Small heat shock proteins differentially affect Abeta aggregation and toxicity. Biochem Biophys Res Commun. 2006;347:527–533
  98. Abid K, Soto C. The intriguing prion disorders. Cell Mol Life Sci. 2006;2342–2357
  99. Aguzzi A. Prion diseases of humans and farm animals: Epidemiology, genetics, and pathogenesis. J Neurochem. 2006;97:1726–1739
  100. Glatzel M, Stoeck K, Seeger H, et al. Human prion diseases: Molecular and clinical aspects. Arch Neurol. 2005;62:545–552
  101. Griffith JS. Self-replication and scrapie. Nature. 1967;215:1043–1044
  102. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–144
  103. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry. 2005;76:906–919
  104. Ma J, Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science. 2002;298:1785–1788
  105. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552–1555
  106. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77–79
  107. Wyttenbach A, Sauvageot O, Carmichael J, et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet. 2002;11:1137–1151
  108. Fischbeck KH. Polyglutamine expansion neurodegenerative disease. Brain Res Bull. 2001;56:161–163
  109. Penney JB, Young AB, Shoulson I, et al. Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5:93–99
  110. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369–384
  111. DiFiglia M. Clinical genetics II (Huntington’s disease: from the gene to pathophysiology). Am J Psychiatry. 1997;154:1046
  112. Davies SW, Beardsall K, Turmaine M, et al. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?. Lancet. 1998;351:131–133
  113. Saudou F, Finkbeiner S, Devys D, et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55–66
  114. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805–810
  115. Chai Y, Koppenhafer SL, Bonini NM, et al. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci. 1999;19:10338–10347
  116. Jana NR, Tanaka M, Wang G, et al. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum Mol Genet. 2000;9:2009–2018
  117. Muchowski PJ, Schaffar G, Sittler A, et al. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A. 2000;97:7841–7846
  118. Kobayashi Y, Sobue G. Protective effect of chaperones on polyglutamine diseases. Brain Res Bull. 2001;56:165–168
  119. Zhou H, Li SH, Li XJ. Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. J Biol Chem. 2001;276:48417–48424
  120. Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93:939–949
  121. Warrick JM, Chan HY, Gray-Board GL, et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet. 1999;23:425–428
  122. Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science. 2003;300:1142–1145
  123. Hansson O, Nylandsted J, Castilho RF, et al. Overexpression of heat shock protein 70 in R6/2 Huntington’s disease mice has only modest effects on disease progression. Brain Res. 2003;970:47–57
  124. Cummings CJ, Sun Y, Opal P, et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001;10:1511–1518
  125. Adachi H, Katsuno M, Minamiyama M, et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci. 2003;23:2203–2211
  126. Sanchez Y, Lindquist SL. HSP104 required for induced thermotolerance. Science. 1990;248:1112–1115
  127. Schirmer EC, Glover JR, Singer MA, et al. HSP100/Clp proteins: A common mechanism explains diverse functions. Trends Biochem Sci. 1996;21:289–296
  128. Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A. 2000;97:1589–1594
  129. Meriin AB, Zhang X, Miliaras NB, et al. Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol Cell Biol. 2003;23:7554–7565
  130. Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins. Cell. 1998;94:73–82
  131. Shorter J, Lindquist S. Navigating the ClpB channel to solution. Nat Struct Mol Biol. 2005;12:4–6
  132. Shorter J, Lindquist S. Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell. 2006;23:425–438
  133. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000;408:101–106
  134. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000;287:1837–1840
  135. Willingham S, Outeiro TF, DeVit MJ, et al. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science. 2003;302:1769–1772
  136. Nollen EA, Garcia SM, van Haaften G, et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A. 2004;101:6403–6408
  137. Venkatraman P, Wetzel R, Tanaka M, et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell. 2004;14:95–104
  138. Rego AC, de Almeida LP. Molecular targets and therapeutic strategies in Huntington’s disease. Curr Drug Targets CNS Neurol Disord. 2005;4:361–381
  139. Outeiro TF, Giorgini F. Yeast as a drug discovery platform in Huntington’s and Parkinson’s diseases. Biotechnol J. 2006;1:258–269
  140. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 2005;6:11–22
  141. Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 2006;273:1331–1349
  142. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004;23:2907–2918
  143. Prodromou C, Roe SM, O’Brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997;90:65–75
  144. Zou J, Guo Y, Guettouche T, et al. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94:471–480
  145. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22:304–311
  146. Goldberg AL, Rock K. Not just research tools–proteasome inhibitors offer therapeutic promise. Nat Med. 2002;8:338–340

 T.F.O. was supported in part by a Tosteson Award from the MBRC.

PII: S1071-9091(06)00162-8

doi: 10.1016/j.spen.2006.11.005

Seminars in Pediatric Neurology
Volume 14, Issue 1 , Pages 15-25 , March 2007

Article Tools

* Image Usage & Resolution